Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas S Griffith

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
The Journal of Urology|October 16, 2007
Predicting bacillus Calmette-Guerin immunotherapy effectivenessThomas S Griffith
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Induction of tumor cell apoptosis by TRAIL gene therapyThomas S Griffith
Chemical Immunology and Allergy|February 1, 2007
The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune responseThomas A Ferguson, Thomas S Griffith
Immunological Reviews|September 16, 2006
A vision of cell death: Fas ligand and immune privilege 10 years laterThomas A Ferguson, Thomas S Griffith
European Journal of Pharmacology|October 20, 2009
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapiesPeter A Holoch, Thomas S Griffith
Cancers|July 30, 2016
CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasKatherine A Murphy, Thomas S Griffith
Cancer Research|December 20, 2007
Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapyRebecca L VanOosten, Thomas S Griffith
Oncoimmunology|November 22, 2012
Activation of systemic antitumor immunity via TRAIL-induced apoptosisBritnie R James, Thomas S Griffith
Lab Animal|October 9, 2019
A wild microbiome improves mouse modeling of the human immune responseSara E Hamilton, Thomas S Griffith
Immunity|November 1, 2011
Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cellsThomas S Griffith, Thomas A Ferguson
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
The Journal of Urology|October 16, 2007
Predicting bacillus Calmette-Guerin immunotherapy effectivenessThomas S Griffith
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Induction of tumor cell apoptosis by TRAIL gene therapyThomas S Griffith
Chemical Immunology and Allergy|February 1, 2007
The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune responseThomas A Ferguson, Thomas S Griffith
Immunological Reviews|September 16, 2006
A vision of cell death: Fas ligand and immune privilege 10 years laterThomas A Ferguson, Thomas S Griffith
European Journal of Pharmacology|October 20, 2009
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapiesPeter A Holoch, Thomas S Griffith
Cancers|July 30, 2016
CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasKatherine A Murphy, Thomas S Griffith
Cancer Research|December 20, 2007
Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapyRebecca L VanOosten, Thomas S Griffith
Oncoimmunology|November 22, 2012
Activation of systemic antitumor immunity via TRAIL-induced apoptosisBritnie R James, Thomas S Griffith
Lab Animal|October 9, 2019
A wild microbiome improves mouse modeling of the human immune responseSara E Hamilton, Thomas S Griffith
Immunity|November 1, 2011
Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cellsThomas S Griffith, Thomas A Ferguson
Pageof 18